On Nov 3, 2021 Clade Therapeutics closed a Series A round and raised $87,000,000 from Bristol Myers Squibb, Emerson Collective, LifeSci Venture Partners, Syncona Partners LLP, featuring lead investors Syncona Partners LLP.

About the company: Clade Therapeutics is located at United States, North America.
“Clade Therapeutics’ platform technology immune “cloaks” human pluripotent stem cells and their adult derivatives enabling the development of true ‘off-the-shelf’ cell transplantation therapies.”

Company website: http://www.cladetx.com